First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions

Advanced Solid TumorsMetastatic Solid Tumors

Interventions

DRUG

JSKN003

JSKN003 is to be administered via intravenous (IV) dose

Trial Locations (1)

Breast Cancer Research Centre, Perth

All Listed Sponsors

lead

Alphamab (Australia) Co Pty Ltd.

INDUSTRY